Biomarkers of COVID-19 severity may not serve patients with polycystic ovary syndrome
<p dir="ltr">In a cohort of patients with differing severity of COVID-19 disease, including non-survivors, plasma proteomic analysis identified biomarkers of COVID-19 disease progression [1]. The top pathways identified by Shu et al. were those of platelet degranulation and the compl...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , |
| منشور في: |
2021
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513517755826176 |
|---|---|
| author | Abu Saleh Md Moin (6189512) |
| author2 | Manjula Nandakumar (1545811) Thozhukat Sathyapalan (704787) Stephen L. Atkin (6684368) Alexandra E. Butler (6189536) |
| author2_role | author author author author |
| author_facet | Abu Saleh Md Moin (6189512) Manjula Nandakumar (1545811) Thozhukat Sathyapalan (704787) Stephen L. Atkin (6684368) Alexandra E. Butler (6189536) |
| author_role | author |
| dc.creator.none.fl_str_mv | Abu Saleh Md Moin (6189512) Manjula Nandakumar (1545811) Thozhukat Sathyapalan (704787) Stephen L. Atkin (6684368) Alexandra E. Butler (6189536) |
| dc.date.none.fl_str_mv | 2021-02-11T03:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1186/s12967-021-02723-7 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Biomarkers_of_COVID-19_severity_may_not_serve_patients_with_polycystic_ovary_syndrome/25712286 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Medical biotechnology Biomarkers Polycystic ovary syndrome COVID-19 SARS-CoV-2 Platelet degranulation Coagulation factors |
| dc.title.none.fl_str_mv | Biomarkers of COVID-19 severity may not serve patients with polycystic ovary syndrome |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p dir="ltr">In a cohort of patients with differing severity of COVID-19 disease, including non-survivors, plasma proteomic analysis identified biomarkers of COVID-19 disease progression [1]. The top pathways identified by Shu et al. were those of platelet degranulation and the complement and coagulation cascades [1]. These identified pathways were complementary to another recent study comparing COVID-19 disease and control subjects, where proteomic panels also identified biological pathways involved in platelet degranulation and the coagulation cascade [2]. Whilst the comparison with absolute disease-free normality is relevant, an increasing proportion of the population have insulin resistant states with associated metabolic conditions; an example of such a metabolic condition is polycystic ovary syndrome (PCOS) where it has been shown that protein expression patterns may differ compared to those without PCOS [3]. Notably, in PCOS, platelet aggregation enhancement together with aberrant diminished plasma fibrinolytic activity potentially giving rise to enhanced thrombosis has been described [4, 5], with markers of coagulation being enhanced [6].</p><p dir="ltr"><br></p><p dir="ltr">For a protein biomarker to be of value, there needs to be a clear discrimination between normal and disease condition levels. Therefore, platelet degranulation and the complement and coagulation cascade proteomic analysis was performed in women with and without PCOS to compare with these pathways described in COVID-19 disease [1].</p><p dir="ltr"><br></p><p dir="ltr">243 subjects (146 PCOS and 97 control women) were recruited to the local PCOS biobank (ISRCTN70196169) [3] in the Department of Endocrinology, Hull and East Yorkshire Hospitals NHS Trust. The Rotterdam consensus diagnostic criteria were used to diagnose PCOS. Proteins that were described for platelet degranulation (18 of 27 proteins) and the complement and coagulation cascades (16 of 19 proteins) [1] were measured using the Slow Off-rate Modified Aptamer (SOMA)-scan plasma protein measurement [7], shown in Table 1. Statistics were performed using Graphpad Prism 8.0.</p><h2>Other Information</h2><p dir="ltr">Published in: Journal of Translational Medicine<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1186/s12967-021-02723-7" target="_blank">https://dx.doi.org/10.1186/s12967-021-02723-7</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_233f9a8ce27919f4aebca5620ed25aa4 |
| identifier_str_mv | 10.1186/s12967-021-02723-7 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/25712286 |
| publishDate | 2021 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Biomarkers of COVID-19 severity may not serve patients with polycystic ovary syndromeAbu Saleh Md Moin (6189512)Manjula Nandakumar (1545811)Thozhukat Sathyapalan (704787)Stephen L. Atkin (6684368)Alexandra E. Butler (6189536)Biomedical and clinical sciencesMedical biotechnologyBiomarkersPolycystic ovary syndromeCOVID-19SARS-CoV-2Platelet degranulationCoagulation factors<p dir="ltr">In a cohort of patients with differing severity of COVID-19 disease, including non-survivors, plasma proteomic analysis identified biomarkers of COVID-19 disease progression [1]. The top pathways identified by Shu et al. were those of platelet degranulation and the complement and coagulation cascades [1]. These identified pathways were complementary to another recent study comparing COVID-19 disease and control subjects, where proteomic panels also identified biological pathways involved in platelet degranulation and the coagulation cascade [2]. Whilst the comparison with absolute disease-free normality is relevant, an increasing proportion of the population have insulin resistant states with associated metabolic conditions; an example of such a metabolic condition is polycystic ovary syndrome (PCOS) where it has been shown that protein expression patterns may differ compared to those without PCOS [3]. Notably, in PCOS, platelet aggregation enhancement together with aberrant diminished plasma fibrinolytic activity potentially giving rise to enhanced thrombosis has been described [4, 5], with markers of coagulation being enhanced [6].</p><p dir="ltr"><br></p><p dir="ltr">For a protein biomarker to be of value, there needs to be a clear discrimination between normal and disease condition levels. Therefore, platelet degranulation and the complement and coagulation cascade proteomic analysis was performed in women with and without PCOS to compare with these pathways described in COVID-19 disease [1].</p><p dir="ltr"><br></p><p dir="ltr">243 subjects (146 PCOS and 97 control women) were recruited to the local PCOS biobank (ISRCTN70196169) [3] in the Department of Endocrinology, Hull and East Yorkshire Hospitals NHS Trust. The Rotterdam consensus diagnostic criteria were used to diagnose PCOS. Proteins that were described for platelet degranulation (18 of 27 proteins) and the complement and coagulation cascades (16 of 19 proteins) [1] were measured using the Slow Off-rate Modified Aptamer (SOMA)-scan plasma protein measurement [7], shown in Table 1. Statistics were performed using Graphpad Prism 8.0.</p><h2>Other Information</h2><p dir="ltr">Published in: Journal of Translational Medicine<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1186/s12967-021-02723-7" target="_blank">https://dx.doi.org/10.1186/s12967-021-02723-7</a></p>2021-02-11T03:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1186/s12967-021-02723-7https://figshare.com/articles/journal_contribution/Biomarkers_of_COVID-19_severity_may_not_serve_patients_with_polycystic_ovary_syndrome/25712286CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/257122862021-02-11T03:00:00Z |
| spellingShingle | Biomarkers of COVID-19 severity may not serve patients with polycystic ovary syndrome Abu Saleh Md Moin (6189512) Biomedical and clinical sciences Medical biotechnology Biomarkers Polycystic ovary syndrome COVID-19 SARS-CoV-2 Platelet degranulation Coagulation factors |
| status_str | publishedVersion |
| title | Biomarkers of COVID-19 severity may not serve patients with polycystic ovary syndrome |
| title_full | Biomarkers of COVID-19 severity may not serve patients with polycystic ovary syndrome |
| title_fullStr | Biomarkers of COVID-19 severity may not serve patients with polycystic ovary syndrome |
| title_full_unstemmed | Biomarkers of COVID-19 severity may not serve patients with polycystic ovary syndrome |
| title_short | Biomarkers of COVID-19 severity may not serve patients with polycystic ovary syndrome |
| title_sort | Biomarkers of COVID-19 severity may not serve patients with polycystic ovary syndrome |
| topic | Biomedical and clinical sciences Medical biotechnology Biomarkers Polycystic ovary syndrome COVID-19 SARS-CoV-2 Platelet degranulation Coagulation factors |